AP
BMY.RT

Atwood & Palmer’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Atwood & Palmer’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-520
Closed – – 460
2020
Q4 		$0 Hold
520
– – ﹤0.01% 395
2020
Q3 		$1K Sell
520
-1,600
-75% -$4.57K ﹤0.01% 330
2020
Q2 		$8K Hold
2,120
– – ﹤0.01% 272
2020
Q1 		$8K Hold
2,120
– – ﹤0.01% 263
2019
Q4 		$6K Buy
+2,120
New +$5.51K ﹤0.01% 270

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Atwood & Palmer's BMY.RT Position: Q1 2021 in Review

Atwood & Palmer sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 520 shares.

Atwood & Palmer first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $8K in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Atwood & Palmer reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Atwood & Palmer sold 520 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021.
  • Atwood & Palmer first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Atwood & Palmer's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $8K in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Atwood & Palmer's 13F filing for Q1 2021, filed 26 Apr 2021.